Tags

Type your tag names separated by a space and hit enter

A phase II clinical trial of mefloquine in Brazilian male subjects.
Bull World Health Organ. 1983; 61(5):815-20.BW

Abstract

Mefloquine was compared with sulfadoxine-pyrimethamine for safety and efficacy in a randomized, double-blind clinical trial in adult males from a malaria-endemic area of Brazil. A total of 99 oligosymptomatic and symptomatic volunteers with Plasmodium falciparum parasitaemia took part in the trial; 49 were given 1000 mg of mefloquine and the remainder received 1500 mg of sulfadoxine plus 75 mg of pyrimethamine, in a single oral dose.Mefloquine was 100% successful in clearing parasitaemia within 7 days; there were no recrudescences. Sulfadoxine-pyrimethamine was less successful; 35 cases showed an S-type response, 8 an RI response, 3 an RII, and 2 an RIII response. The side-effects of mefloquine were mild and transient and included headache, nausea, vomiting, dizziness, and diarrhoea. A satisfactory weight gain and rise in haemoglobin level were seen in both groups.

Links

PMC Free PDF
PMC Free Full Text

Authors

de Souza JM
No affiliation info available

MeSH

AdultAntimalarialsDouble-Blind MethodDrug EvaluationDrug Therapy, CombinationHumansMalariaMaleMefloquinePlasmodium falciparumPyrimethamineQuinolinesRandom AllocationSulfadoxine

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

6360401

Citation

de Souza, J M.. "A Phase II Clinical Trial of Mefloquine in Brazilian Male Subjects." Bulletin of the World Health Organization, vol. 61, no. 5, 1983, pp. 815-20.
de Souza JM. A phase II clinical trial of mefloquine in Brazilian male subjects. Bull World Health Organ. 1983;61(5):815-20.
de Souza, J. M. (1983). A phase II clinical trial of mefloquine in Brazilian male subjects. Bulletin of the World Health Organization, 61(5), 815-20.
de Souza JM. A Phase II Clinical Trial of Mefloquine in Brazilian Male Subjects. Bull World Health Organ. 1983;61(5):815-20. PubMed PMID: 6360401.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A phase II clinical trial of mefloquine in Brazilian male subjects. A1 - de Souza,J M, PY - 1983/1/1/pubmed PY - 1983/1/1/medline PY - 1983/1/1/entrez SP - 815 EP - 20 JF - Bulletin of the World Health Organization JO - Bull World Health Organ VL - 61 IS - 5 N2 - Mefloquine was compared with sulfadoxine-pyrimethamine for safety and efficacy in a randomized, double-blind clinical trial in adult males from a malaria-endemic area of Brazil. A total of 99 oligosymptomatic and symptomatic volunteers with Plasmodium falciparum parasitaemia took part in the trial; 49 were given 1000 mg of mefloquine and the remainder received 1500 mg of sulfadoxine plus 75 mg of pyrimethamine, in a single oral dose.Mefloquine was 100% successful in clearing parasitaemia within 7 days; there were no recrudescences. Sulfadoxine-pyrimethamine was less successful; 35 cases showed an S-type response, 8 an RI response, 3 an RII, and 2 an RIII response. The side-effects of mefloquine were mild and transient and included headache, nausea, vomiting, dizziness, and diarrhoea. A satisfactory weight gain and rise in haemoglobin level were seen in both groups. SN - 0042-9686 UR - https://www.unboundmedicine.com/medline/citation/6360401/A_phase_II_clinical_trial_of_mefloquine_in_Brazilian_male_subjects_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/6360401/ DB - PRIME DP - Unbound Medicine ER -